The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

On November 11, 2025, Sanofi and Regeneron announced that the FDA accepted for priority review its supplemental biologics license application ...

Morning nasal congestion can signal allergies, sinusitis, dry air, GERD, or structural nasal issues. ENT experts say that ...

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes ...

The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), ...

LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...

Dr Ray O’Connor continues his look at recent clinical articles on therapeutics, with an emphasis on antibiotics, postbiotics, and faecal transplantation ...

Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...

Following its maiden flight in September, a "flying eye and ENT hospital" — a joint project between the Shanghai-based Eye ...

The MarketWatch News Department was not involved in the creation of this content.-- Omlyclo(TM) (omalizumab) is the first and only omalizumab biosimilar approved in Europe -- Omly ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE ...